Who we are
A team of highly skilled scientific staff that undertake the primary contract business. We have huge expertise in all the necessary fields and are able to provide a complete service to the customer from molecule to monoclonal. The OxFabs team believes its services are of the highest quality and a genuinely thorough, analytical approach is taken in the characterisation of the reagents. This is to the advantage of the customer ensuring their subsequent work is not compromised.
The OxFabs manager made the first bcl-2 monoclonal in 1990. This is used to detect the (14;18) translocation, the signature when diagnosing follicular lymphoma. Also of note is the CD45RB antibody PD-7/26, which allows the pathologist to distinguish between lymphoma and carcinoma. In particular, when the morphology can be extremely poor, it aids in rapid diagnosis, which can be of extreme benefit to the patient. She has also made monoclonals to CD79a (for the diagnosis of B cell tumours), CD8, CD5, CD31 and CD61 (to name but a few), all of which are paraffin reactive antibodies and permit the pathologist to determine the cell of origin in neoplastic samples.
Our senior scientist has over 20 years experience in immunohistochemistry and immunofluorescence. She pioneered the ImmunoFISH method, on paraffin sections, where she combines staining with an antibody to detect the exact origin of which cell contains a translocation or amplification signal of a FISH probe.
